InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Propanc Biopharma, Inc.

PPCB Clue Score29
Australia Fiscal year ends June CIK 0001517681
$0.44 -9.41% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.44 +1,427.78% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 13 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2017Operating income−5.7Net income−7.9Fiscal year 2018Operating income−4.0Net income−7.0Fiscal year 2019Operating income−2.6Net income−5.8Fiscal year 2020Operating income−3.5Net income−4.7Fiscal year 2021Operating income−1.8Net income−2.0Fiscal year 2022Operating income−2.0Net income−2.7EPS, diluted−49.23Fiscal year 2023Operating income−1.8Net income−2.7EPS, diluted−1.80Fiscal year 2024Operating income−1.5Net income−1.8EPS, diluted−1,420.53Fiscal year 2025Operating income−57.3Net income−58.9EPS, diluted−371.22Fiscal year 2026Operating income−18.2Net income−18.9EPS, diluted−17.62
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating income −5.7 −4.0 −2.6 −3.5 −1.8 −2.0 −1.8 −1.5 −57.3 −18.2
Net income −7.9 −7.0 −5.8 −4.7 −2.0 −2.7 −2.7 −1.8 −58.9 −18.9
Growth
EPS, diluted n/a n/a n/a n/a n/a −49.23 −1.80 −1,420.53 −371.22 −17.62

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−2.1Fiscal year 2018Operating cash flow−2.2Fiscal year 2019Operating cash flow−2.1Capital expenditure−0.0Free cash flow−2.1Fiscal year 2020Operating cash flow−1.8Fiscal year 2021Operating cash flow−1.1Fiscal year 2022Operating cash flow−1.4Fiscal year 2023Operating cash flow−1.1Fiscal year 2024Operating cash flow−0.9Fiscal year 2025Operating cash flow−0.4Fiscal year 2026Operating cash flow−5.7Capital expenditure−0.0Free cash flow−5.7
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −2.1 −2.2 −2.1 −1.8 −1.1 −1.4 −1.1 −0.9 −0.4 −5.7
Capital expenditure n/a n/a −0.0 n/a n/a n/a n/a n/a n/a −0.0
Free cash flow n/a n/a −2.1 n/a n/a n/a n/a n/a n/a −5.7
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2017Total debt3.5Shareholders’ equity−5.4Fiscal year 2018Total debt4.7Shareholders’ equity−6.8Fiscal year 2019Total debt1.7Shareholders’ equity−4.3Fiscal year 2020Cash0.1Total debt1.6Net cash (debt)−1.5Shareholders’ equity−3.6Fiscal year 2021Cash0.0Total debt0.6Net cash (debt)−0.6Shareholders’ equity−3.1Fiscal year 2022Cash0.0Total debt0.9Net cash (debt)−0.9Shareholders’ equity−3.0Fiscal year 2023Total debt0.4Shareholders’ equity−3.1Fiscal year 2024Total debt0.4Shareholders’ equity−3.8Fiscal year 2025Total debt0.5Shareholders’ equity13.9Debt to equity0.04Fiscal year 2026Shareholders’ equity9.4
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash n/a n/a n/a 0.1 0.0 0.0 n/a n/a n/a n/a
Total debt 3.5 4.7 1.7 1.6 0.6 0.9 0.4 0.4 0.5 n/a
Net cash (debt) n/a n/a n/a −1.5 −0.6 −0.9 n/a n/a n/a n/a
Shareholders’ equity −5.4 −6.8 −4.3 −3.6 −3.1 −3.0 −3.1 −3.8 13.9 9.4
Debt to equity n/a n/a n/a n/a n/a n/a n/a n/a 0.04 n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending June, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 30 Jun 2017 FY2018 30 Jun 2018 FY2019 30 Jun 2019 FY2020 30 Jun 2020 FY2021 30 Jun 2021 FY2022 30 Jun 2022 FY2023† 30 Jun 2023 FY2024† 30 Jun 2024 FY2025† 30 Jun 2025 FY2026† 30 Jun 2026
Revenue and profit
0.0 0.0 0.0 n/a n/a n/a n/a n/a n/a n/a
1.0 1.8 0.3 0.2 0.2 0.3 0.2 0.2 0.2 0.6
4.7 2.1 2.3 3.3 1.6 1.7 1.5 1.3 0.1 0.7
−5.7 −4.0 −2.6 −3.5 −1.8 −2.0 −1.8 −1.5 −57.3 −18.2
Growth
n/a −7.0 −5.8 −4.9 −2.1 −2.7 −2.8 −1.9 −58.9 −18.9
−0.3 −0.2 −0.1 −0.1 −0.1 −0.1 −0.1 −0.1 n/a n/a
−7.9 −7.0 −5.8 −4.7 −2.0 −2.7 −2.7 −1.8 −58.9 −18.9
Growth
Per share
n/a n/a n/a n/a −0.80 −49.23 −1.80 −1,420.53 −371.22 −17.62
n/a n/a n/a n/a n/a −49.23 −1.80 −1,420.53 −371.22 −17.62
Growth
n/a n/a n/a n/a 3.0 0.1 1.7 0.0 0.2 1.1
n/a n/a n/a n/a n/a 0.1 1.7 0.0 0.2 1.1
Growth +2,448.9% −99.9% +11,101.6% +608.0%

† The diluted share count jumps at 2023 and 2024 and 2025 and 2026, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 10 of 10 years on file.